Compare PACK & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | SIGA |
|---|---|---|
| Founded | 1972 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.2M | 486.2M |
| IPO Year | 2017 | 2016 |
| Metric | PACK | SIGA |
|---|---|---|
| Price | $3.83 | $5.59 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 551.4K | 395.1K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.35% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | ★ $395,000,000.00 | N/A |
| Revenue This Year | $11.99 | N/A |
| Revenue Next Year | $8.16 | $132.36 |
| P/E Ratio | ★ N/A | $14.48 |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $2.91 | $4.95 |
| 52 Week High | $6.31 | $9.62 |
| Indicator | PACK | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 27.57 | 31.13 |
| Support Level | $3.34 | $5.21 |
| Resistance Level | $6.01 | $6.98 |
| Average True Range (ATR) | 0.32 | 0.25 |
| MACD | -0.19 | -0.13 |
| Stochastic Oscillator | 12.44 | 20.58 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. Geographically, it derives a majority of its revenue from Europe/Asia. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.